A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase Over Intravenous Pembrolizumab Formulation in Multiple Tumor Types
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will